Advanced

AJNR - American Journal of Neuroradiology

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Adalsteinsson, E. Articles by Atlas, S. W. Search for Related Content PubMed PubMed Citation Articles by Adalsteinsson, E. Articles by Atlas, S. W.

American Journal of Neuroradiology 24:1941-1945, November-December 2003
© 2003 American Society of Neuroradiology

BRAIN

Gray Matter N-Acetyl Aspartate Deficits in Secondary Progressive but Not Relapsing-Remitting Multiple Sclerosis

Elfar Adalsteinsson^a, Annette Langer-Gould^b, Ronald J. Homer^a, Archana Rao^a, Edith V. Sullivan^c, Christiane Abbehusen Lima^a, Adolf Pfefferbaum^c,d and Scott W. Atlas^a

^a Department of Radiology, Stanford University School of Medicine, Stanford, CA
^b Department of Neurology, Stanford University School of Medicine, Stanford, CA
^c Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
^d Neuroscience Program, SRI International, Menlo Park, CA

Address correspondence to Elfar Adalsteinsson, PhD, Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305

BACKGROUND AND PURPOSE: Spectroscopic examination of multiple sclerosis (MS) patients has revealed abnormally low N-acetyl-aspartate (NAA) signal intensity, even in brain tissue that appears normal on high-resolution structural MR images but has yielded inconclusive evidence to distinguish the well-documented clinical differences between MS subtypes. This study used proton MR spectroscopic imaging (MRSI) and high-resolution MR imaging to characterize metabolite profiles in normal-appearing brain tissue of relapsing-remitting multiple sclerosis (RRMS) and secondary progressive (SP) MS.

METHODS: Volumetric spiral MRSI was used together with high-resolution MR imaging to derive absolute measures of metabolite concentrations separately in normal-appearing supratentorial cerebral gray matter and white matter in five RRMS patients, five SPMS patients, and nine age-matched controls. Structural MR images were segmented into compartments of gray matter, white matter, CSF, and lesions, and metabolite signals per unit of tissue volume were calculated for gray matter and white matter separately.

RESULTS: Only the SPMS group had significantly lower NAA concentrations in normal-appearing gray matter compared with concentrations in controls. NAA in normal-appearing white matter was equally reduced in RRMS and SPMS patients. The functional relevance of this brain metabolite measure was suggested by the observed but statistically nonsignificant correlation between higher disability scores on the Expanded Disability Status Scale and lower gray matter NAA concentrations.

CONCLUSION: The otherwise occult abnormality in supratentorial gray matter in SPMS but not RRMS may explain the more severe physical and cognitive impairments afflicting patients with SPMS that do not correlate well with visible lesion burden.

This article has been cited by other articles:

				N. De Stefano, M. Filippi, D. Miller, P. J. Pouwels, A. Rovira, A. Gass, C. Enzinger, P. M. Matthews, and D. L. Arnold Guidelines for using proton MR spectroscopy in multicenter clinical MS studies Neurology, November 13, 2007; 69(20): 1942 - 1952. [Abstract] [Full Text] [PDF]

				A. Pulizzi, M. Rovaris, E. Judica, M. P. Sormani, V. Martinelli, G. Comi, and M. Filippi Determinants of Disability in Multiple Sclerosis at Various Disease Stages: A Multiparametric Magnetic Resonance Study Arch Neurol, August 1, 2007; 64(8): 1163 - 1168. [Abstract] [Full Text] [PDF]

				H. Vrenken, P.J.W. Pouwels, S. Ropele, D.L. Knol, J.J.G. Geurts, C.H. Polman, F. Barkhof, and J.A. Castelijns Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease Multiple Sclerosis, July 1, 2007; 13(6): 708 - 716. [Abstract] [PDF]

				H. Vrenken, J. J. G. Geurts, D. L. Knol, L. N. van Dijk, V. Dattola, B. Jasperse, R. A. van Schijndel, C. H. Polman, J. A. Castelijns, F. Barkhof, et al. Whole-Brain T1 Mapping in Multiple Sclerosis: Global Changes of Normal-appearing Gray and White Matter Radiology, September 1, 2006; 240(3): 811 - 820. [Abstract] [Full Text] [PDF]

				Z. Caramanos, S. Narayanan, and D. L. Arnold 1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review Brain, November 1, 2005; 128(11): 2483 - 2506. [Abstract] [Full Text] [PDF]